A phase 3, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of elritercept (KER-050) for the treatment of transfusion-dependent anemia in adult participants with very low-, low-, or intermediate-risk myelodysplastic syndromes (MDS) (RENEW)

Description

The main aim of this study is to find out how well elritercept works in lowering the need for RBC transfusions. Other aims are to learn how well elritercept works in reducing the need for RBC transfusions over longer periods of time or in adults with high transfusion needs. The study will also check on how safe elritercept is and how well it is tolerated.

Resources and Links

Phone Number: 1-877-MDA-6789

clinicaltrials.gov NCT No: NCT06499285 Opens a new window